Discovery of Improved Platinum Analogues

  • Kenneth R. Harrap
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)

Abstract

Although dichlorodiammine platinum II (Fig. 1) was first synthesised by Peyrone in 1845, the powerful antitumour properties (confined to the cis-isomer) remained unknown until the work of Barnett Rosenberg, some 125 years later. Rosenberg attributed the toxic effects of an alternating electric field applied to a suspension of E coli to the generation of cis-dichlorodi-ammine platinum II (cisplatin). Subsequently, cisplatin was shown to possess potent activity, both alone and in combination, against a wide spectrum of transplantable rodent tumours [see 1–3 for reviews]. Preclinical toxicology was assessed in mice, rats, guinea pigs, dogs and monkeys and the results predicted well for those toxicities subsequently found in man [4]. Nephrotoxicity was the major dose-limiting side effect in all species, accompanied by gastrointestinal, haematological and ototoxicities, together with severe emesis in dogs and monkeys [5-11].

Keywords

Toxicity Oncol Neutropenia Quinoline Biotransformation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rosenberg B: Platinum complexes for the treatment of cancer. Interdisciplin Sci Rev 1978 (3): 134–147Google Scholar
  2. 2.
    Harrap KR: Platinum analogues: criteria for selection. In: Muggia FM (ed) Cancer Chemotherapy 1. Martinus Nijhoff, Boston 1983 pp 171–217Google Scholar
  3. 3.
    Wolpert-De Filippes MK: Antitumor activity of cis-dichlorodiammine platinum (II). Cancer Treat Rep 1979 (63): 1453–1458Google Scholar
  4. 4.
    Guarino AM, Miller DS, Arnold ST, Pritchard JB, Davis RD, Urbanek MA, Miller TJ, Litterst CL: Platinate toxicity: Past, present and prospects. Cancer Treat Rep 1979 (63): 1475–1483PubMedGoogle Scholar
  5. 5.
    Harrap KR: Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 1985 (12 Suppl A):21–33PubMedGoogle Scholar
  6. 6.
    Schaeppi U, Heyman IA, Fleisehmann RW: Cis-dichlorodiammine platinum(II) (NSC 119875): Preclinical toxicologic evaluation of intravenous injections in dogs, monkeys and mice. Toxicol Appl Pharmacol 1973 (25): 230–241PubMedGoogle Scholar
  7. 7.
    Fleischman RW, Stadnicki SW, Ethier MF, Schaeppi U: Ototoxicity of cis-dichlorodiammine platinum(II) in the guinea pig. Toxicol Appl Pharmacol 1975 (33): 320–332PubMedGoogle Scholar
  8. 8.
    Kociba RJ, Sleight SD: Acute toxicologic and pathologic effects of cis-diamminedichloro platinum (NSC 119875) in the male rat. Cancer Chemother Rep 1971 (55): 1–8PubMedGoogle Scholar
  9. 9.
    Stadnicki SW, Fleischman RW, Schaeppi U, Merriam P: Cis-dichlorodiammine platinum(II) (NSC 119875): Hearing loss and other toxic effects in Rhesus monkeys. Cancer Chemother Rep 1975 (59): 467–480PubMedGoogle Scholar
  10. 10.
    Ward JM, Faucie KA: The nephropathology of cis-diamminedichloroplatinum(II) (NSC 119875) in male F344 rats. Toxicol Appl Pharmacol 1976 (38): 535–547PubMedGoogle Scholar
  11. 11.
    Madias NE, Harrington JT: Platinum nephrotoxicity. Am J Med 1978 (65): 307–314PubMedGoogle Scholar
  12. 12.
    Higby DJ, Wallace HJ, Jr, Albert D, Holland JF: Diamminodichioroplatinum in the chemotherapy of testicular tumors. J Urol 1974 (112): 100–104PubMedGoogle Scholar
  13. 13.
    Merrin CE: Treatment of genitourinary tumours with cis-dichlorodiammine platinum(II): Experience in 250 patients. Cancer Treat Rep 1979 (63): 1579–1584PubMedGoogle Scholar
  14. 14.
    Carter SK, Wasserman TH: The chemotherapy of urologie cancer. Cancer 1975 (36): 729–747PubMedGoogle Scholar
  15. 15.
    Rozencweig M, Von Hoff DD, Catane R, Muggia FM: Platinum complexes in cancer chemotherapy In: Schabel FM (ed) Antibiotics and Chemotherapy. Basel: Karger 1978 (23): 99–112Google Scholar
  16. 16.
    Williams C: Current dilemmas in the management of non-seminomatous germ cell tumors of the testis. Cancer Treat Rev 1977 (4): 275–297PubMedGoogle Scholar
  17. 17.
    Einhorn LH, Donohue JP: Improved chemotherapy in disseminated testicular cancer. J Urol 1977 (117): 65–69PubMedGoogle Scholar
  18. 18.
    Samson MK, Baker LH, Devos JM, Buroker TR, Isbicki RM, Vaitkevicius VK: Phase I clinical trial of combined therapy with vinblastine (NSC 49842), bleomycin (NSC 125066) and cis-dichlorodiammine platinum(II) (NSC 119875). Cancer Treat Rep 1976 (60): 91–97PubMedGoogle Scholar
  19. 19.
    Einhorn LE: Combination chemotherapy with cis-dichlorodiammine platinum(II) in disseminated testicular cancer. Cancer Treat Rep 1979 (63): 1659–1662PubMedGoogle Scholar
  20. 20.
    Samson MK, Stephens RL, Rivkin S, Opipari M, Maloney T, Groppe CW, Fischer R: Vinblastine, bleomycin and cis-dichlorodiammineplatinum II in disseminated testicular cancer: Preliminary report of a South West Oncology Group Study. Cancer Treat Rep 1979 (63): 1663–1667PubMedGoogle Scholar
  21. 21.
    Williams SD, Einhorn LH: Cisplatin chemotherapy of testicular cancer. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin, Current Status and New Developments. Academic Press, New York 1980 pp 323–328Google Scholar
  22. 22.
    Wiltshaw E, Kroner T: Phase II Study of cis-dichlorodiammine platinum(II) (NSC 119875) in advanced carcinoma of the ovary. Cancer Treat Rep 1976 (60): 55–60PubMedGoogle Scholar
  23. 23.
    Bruckner HW, Cohen CJ, Wallach RC, Kabakow B, Deppe G, Greenspan EM, Gusberg SB, Holland JF: Treatment of advanced ovarian cancer with cis-dichlorodiammineplatinum(II): Poor risk patients with intensive prior therapy. Cancer Treat Rep 1978 (62): 555–558PubMedGoogle Scholar
  24. 24.
    Young RC, Von Hoff DD, Gormley P, Makuch R, Cassidy J, Howser D, Bull JM: Cis-dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. Cancer Treat Rep 1979 (63): 1539–1544PubMedGoogle Scholar
  25. 25.
    Wiltshaw E, Carr T: Cis-platinum(II)diamminedichloride: Clinical experience of the Royal Marsden Hospital and Institute of Cancer Research. Recent Results Cancer Res 1974 (48): 178–182Google Scholar
  26. 26.
    Merrin C: Treatment of advanced bladder cancer with cis-diamminedichloroplatinum(II) (NSC 119875): A pilot study. J Urol 1978 (119): 493–495PubMedGoogle Scholar
  27. 27.
    Yagoda A, Watson RC, Gonzalez-Vitale JC, Grabstaldt H, Whitmore WF: Cis-dichlorodiammineplatinum(II) in advanced bladder cancer. Cancer Treat Rep 1976 (60): 917–923PubMedGoogle Scholar
  28. 28.
    Herr HW: Cis-diamminedichloride platinum(II) in the treatment of advanced bladder cancer. J Urol 1980 (123): 853–855PubMedGoogle Scholar
  29. 29.
    Yagoda A: Cisplatin regimens in the treatment of bladder and penile cancer. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin, Current Status and New Developments, Academic Press, New York 1980 pp 361–374Google Scholar
  30. 30.
    Jacobs C: The role of cisplatin in the treatment of recurrent head and neck cancer. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin, Current Status and New Developments. New York: Academic Press 1980 pp 423–432Google Scholar
  31. 31.
    Hong WK, Bhutani E, Shapshay SM, Strong S: Induction chemotherapy of advanced previously untreated squamous cell head and neck cancer with cisplatin and bleomycin. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin, Current Status and New Developments. Academic Press, New York 1980, pp 431–444Google Scholar
  32. 32.
    Rozencweig M, Von Hoff DD, Slavik M, Muggia FM: Cis-diamminedichloroplatinum(II). A new anticancer drug. Ann Int Med 1977 (86): 803–812PubMedGoogle Scholar
  33. 33.
    Prestayko AW, D’Aoust JC, Issell BF, Crooke ST: Cisplatin (cis-diamminedichloroplatinumll). Cancer Treat Rev 1979 (6): 17–39PubMedGoogle Scholar
  34. 34.
    Rozencweig M, Von Hoff DD, Abele R, Muggia FM: Cisplatin. In: Pinedo JM (ed) The EORTC Cancer Chemotherapy Annual I. Exerpta Medica, Amsterdam 1980 pp 107–117Google Scholar
  35. 35.
    Randolph VL, Witles RE: Weekly administration of cis-diamminedichloroplatinum(II) without hydration or osmotic diuresis. Eur J Cancer 1978 (14): 753–756PubMedGoogle Scholar
  36. 36.
    Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS: The renal pathology in clinical trials of cis-platinum(Il) diamminedichloride. Cancer 1977 (39): 1362–1371Google Scholar
  37. 37.
    Dentino M, Luft FC, Yum MN, Williams SD, Einhorn H: Long-term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 1978 (41): 1274–1281PubMedGoogle Scholar
  38. 38.
    Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH: High dose cisplatinum diamminedichloride. Cancer 1977 (39): 1372–1381PubMedGoogle Scholar
  39. 39.
    Krakoff IH: Nephrotoxicity of cis-dichlorodiammineplatinum(II). Cancer Treat Rep 1979 (63): 1523–1525PubMedGoogle Scholar
  40. 40.
    Ozols RF, Corden BJ, Collins J and Young RC: High dose cisplatin in hypertonic saline: renal effects and pharmacokinetics of a 40mg/m2 QD×5 schedule. In: Hacker MP, Douple EB, Krakoff IH (eds) Platinum Coordination Complexes in Cancer Chemotherapy. Martinus Nijhoff, Boston 1984 pp 321–329Google Scholar
  41. 41.
    Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, Muggia FM: Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 1979 (63): 1527–1532Google Scholar
  42. 42.
    Boyd MR: Status of the NCI preclinical antitumor drug discovery screen. PPO Updates 1989 (3): 1–12Google Scholar
  43. 43.
    Wolpert De Fillipes MK: Antitumour activity of cisplatin analogues. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin, Current Status and New Developments. Academic Press, New York 1980 pp 183–192Google Scholar
  44. 44.
    Burchenal JH, Kalaher K, Dew K, Lokys L: Rationale for the development of platinum analogs. Cancer Treat Rep 1979 (63): 1493–1498PubMedGoogle Scholar
  45. 45.
    Burchenal JH, Irani G, Kern K, Lokys L, Turkervich J: 1,2-Diaminocyclohexane platinum derivatives of potential clinical value. Recent Results Cancer Res 1980 (74): 146–155PubMedGoogle Scholar
  46. 46.
    Burchenal JH, Lokys L, Turkevich J, Ramachandran C: Rationale of combination chemotherapy. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin, Current Status and New Developments. Academic Press, New York 1980 pp 113–124Google Scholar
  47. 47.
    Schwartz P, Meischan SJ, Gale GR, Atkins LM, Smith AB, Walker EM Jr: Preparation and antitumour evaluation of water soluble derivatives of dichloro(1,2-diamminocyclohexane)platinum(II). Cancer Treat Rep 1977 (61): 1519–1525PubMedGoogle Scholar
  48. 48.
    Kidani Y, Noji M, Tashiro T: Antitumour activity of platinum (II) complexes of 1,2-diaminocyclohexane isomers. Gann 1980 (71): 637–643PubMedGoogle Scholar
  49. 49.
    Kidani Y, Inagaki K, Iigo M, Hoshi A, Kazuo K: Antitumour activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form. J Med Chem 1978 (21 part 12): 1315–1318PubMedGoogle Scholar
  50. 50.
    Mathé G, Kidani Y, Noji M, Maral R, Borut C, Chenu E: Antitumour activity of I-OHP in mice. Cancer Lett. 1985 (27): 135–143PubMedGoogle Scholar
  51. 51.
    Sekiguchi M, Eriguchi M, Shiroko Y, Akiyama N, Mikamo S: Chemosensitivity screening in virtro of various cultured human cancer cell lines to a new platinum complex. l-OHP: Oxalato (trans 1–1,2–diaminocyclohexane)platinum(II). Annals Oncol 1992(3 Suppl 1):Abs 194Google Scholar
  52. 52.
    Anderson WK, Quagliato DA, Haugwitz RD, Narayanan VL and Wolpert-De Fillipes MK: Synthesis, physical properties and antitumour activity of tetraplatin and related tetrachloroplatinum(IV) stereoisomers of 1,2-diaminocyclohexane. Cancer Treat Rep 1986 (70): 997–1002PubMedGoogle Scholar
  53. 53.
    Gibbons GR, Wyrick S, Chaney SG: Rapid reduction of tetrachloro(D,L-trans) 1,2-diaminocyclohexaneplatinum(IV) (Tetraplatin) in RPMI tissue culture medium. Cancer Res 1989 (49): 1402–1407PubMedGoogle Scholar
  54. 54.
    Carfagna PF, Poma A, Wyrick SD, Holbrook DJ, Chaney SG: Comparisons of tetrachloro (D,L-trans) 1,2-diaminocyclohexaneplatinum(IV) biotransformations in the plasma of Fisher 344 rats at therapeutic and toxic doses. Cancer Chemother Pharmacol 1991 (27): 335–341PubMedGoogle Scholar
  55. 55.
    Rose WC, Schurig JE, Bradner WT, Huftalen JB: Antitumour activity and toxicity of cis-diamminedichloroplatinum (II) analogs. Cancer Treat Rep 1982 (66): 135–146PubMedGoogle Scholar
  56. 56.
    Goddard PM, Valenti MR, Harrap KR: The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary note. Ann Oncol 1991 (2): 535–540PubMedGoogle Scholar
  57. 57.
    Hills CA, Kelland G, Abel G, Siracky J, Wilson AP, Harrap KR: Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer 1989 (59): 527–534Google Scholar
  58. 58.
    Harrap KR, Jones M, Siracky J, Pollard LA, Kelland LR: The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Ann Oncol 1990 (1): 65–76PubMedGoogle Scholar
  59. 59.
    Kelland LR, Jones M, Abel G, Valenti M, Gwynne J, Harrap KR: Human ovarian carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery. Cancer Chemother Pharmacol 1992 (30): 43–50PubMedGoogle Scholar
  60. 60.
    Kelland LA, Murrer BA, Abel G, Harrap KR: Structure-activity relationships in a series of novel platinum(II) and platinum(IV) ammine/amine complexes evaluated against a panel of human ovarian carcinoma cell lines. J Cell Pharmacol 1991 (2): 331–342Google Scholar
  61. 61.
    Giandomenico CM, Abrams MJ, Murrer BA, Vollano JF, Harrap KR, Kelland LR, Morgan SE: Synthesis and reactions of a new class of orally active Pt(IV) antitumour complexes. In: Howell SB (ed) Platinum and Other Metal Coordination Complexes in Cancer Chemotherapy. Plenum Press, New York 1991 pp 93–100Google Scholar
  62. 62.
    Harrap KR, Murrer BA, Giandomenico C, Morgan SA, Kelland LR, Jones M, Goddard PM and Schurig J: Ammine/amine platinum(IV) dicarboxylates: a novel class of complexes which circumvent intrinsic cisplatin resistance. In: Howell SB (ed) Platinum and Other Metal Coordination Complexes in Cancer Chemotherapy. Plenum Press, New York 1991 pp 391–399Google Scholar
  63. 63.
    Harrap KR, Kelland LR, Jones M, Goddard PM, Orr RM, Morgan SE, Murrer BA, Abrams MJ, and Giandomenico CM: Platinum coordination complexes which circumvent cisplatin resistance. Adv Enzyme Regulation 1991 (31): 31–43Google Scholar
  64. 64.
    McKeage MJ, Morgan SE, Boxall FE, Hard GC, Murrer B, Judson I, Harrap KR: Acute toxicology of orally administered bis-acetato-ammine dichloro(cyclohexylamine)platinum(IV) (JM216) in rodents. Proc Amer Assoc Cancer Res 1992 (33) Abs 3197Google Scholar
  65. 65.
    De Graeff A, Slebos RJC, Rodenhuis S: Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother Pharmacol 1988 (22): 325–332PubMedGoogle Scholar
  66. 66.
    Andrews PA, Howell SB: Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells (Cold Spring Harbor) 1990 (2): 35–43Google Scholar
  67. 67.
    McKeage MJ, Higgins JD (III), Kelland LR: Platinum and other metal coordination compounds in cancer chemotherapy. Br J Cancer 1991 (64): 788–792PubMedGoogle Scholar
  68. 68.
    Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P, Harrap KR: Ammine/amine platinum (IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian cell lines. Cancer Res 1992 (52): 822–828PubMedGoogle Scholar
  69. 69.
    Kelland LR, Mistry P, Abel G, Loh SY, O’Neill CF, Murrer BA, Harrap KR: Mechanism-related circumvention of cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res 1992 (52): 3857–3864PubMedGoogle Scholar
  70. 70.
    Knox RJ, Friedlos F, Lydall DA, Roberts JJ: Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis-diamminedichloro-platinum(II) and cis-diammine (1,1-cyclobutane-dicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986 (46): 1972–1979PubMedGoogle Scholar
  71. 71.
    Farrell N, Qu Y, Hacker MP: Cytotoxicity and antitumor activity of bis(platinum) complexes. A novel class of platinum complexes active in cell lines resistant to both cisplatin and 1,2-diaminocyclohexane complexes. J Med Chem 1990 (33): 2179–2184PubMedGoogle Scholar
  72. 72.
    Farrell N, Qu Y, Feng L, Van Houten B: Comparison of chemical reactivity, cytotoxicity, interstrand cross linking and DNA sequence specificity of bis(platinum) complexes containing monodentate of bidentate coordination spheres with their monomeric analogues. Biochem 1990 (29) 9522–9531Google Scholar
  73. 73.
    Van Beusichem M, Farrell N: Activation of the trans geometry in platinum antitumor complexes. Synthesis, characterisation and biological activity of complexes with the planar ligands pyridine, N-methylimidazole, thiazole and quinoline. Crystal and molecular structure of trans-dichlorobis(thiazole)platinum(II). Inog Chem 1992 (31)634–639Google Scholar
  74. 74.
    Farrell N, Kelland LR, Roberts JD, Van Beusichem M: Activation of the trans geometry in platinum antitumor complexes: A survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Res 1992 (52): 5065–5072PubMedGoogle Scholar
  75. 75.
    Hill JM, Loeb E, Pardue A, Khan A, King JJ, Akman C, Hill NO: Platinum analogs of clinical interest. Cancer Treat Rep 1979 (63): 1509–1513PubMedGoogle Scholar
  76. 76.
    Ribaud P, Alcock N, Burchenal JH, Young C, Muggia F, Mathe G: Preclinical trial in a phase I-Il trial and pharmacokinetics in man of malonato-platinum (MP) Proc Am Soc Clin Oncol 1979 (20): 336Google Scholar
  77. 77.
    Ribaud P, Kelsen DP, Alcock N, Garcia-Giralt E, Dulbouch P, Young CC, Muggia FM, Burchenal JH, Mathe G: Preclinical and phase I studies of malonatoplatinum. Recent Results Cancer Res 1980 (74): 156–162PubMedGoogle Scholar
  78. 78.
    Kelsen DP, Scher H, Alcock N et al: Phase I clinical trial and pharmacokinetics of 4’carboxy-phthalato(1,2-diaminocyclohexane) platinum(II). Cancer Res 1982 (42): 4831–4835PubMedGoogle Scholar
  79. 79.
    Kelsen DP, Scher H, Burchenal J: Phase I and early phase II trials of 4’carboxyphthalato (1,2-diaminocyclohexane) platinum II. In: Hacker MP, Douple EB, Krakoff IH (eds) Platinum Coordination Complexes in Cancer Chemotherapy. Martinus Nijhoff, Boston 1984 pp 310–320Google Scholar
  80. 80.
    Christian MC, Kohn E, Sarosy G, Link C, Davis P, Adams D, Weiss RB, Brewster L, Lombardo F, Reed E: Phase I and pharmacologic study of ormaplatin (OP)/tetraplatin. Proc Amer Soc Clin Oncol 1992 (11): Abs 291Google Scholar
  81. 81.
    Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Robins HI, Spriggs DR: Phase I and pharmacokinetic study of ormaplatin. Proc Amer Assoc Cancer Res 1992 (33): Abs 3202Google Scholar
  82. 82.
    Schilder RJ, La Creta FP, Pereg RP, Nash S, Hamilton TC, Goldstein LJ, Young RC, Ozols RF, O’Dwyer PJ: Phase I/pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812). Proc Amer Assoc Cancer Res 1992 (33): Abs 3211Google Scholar
  83. 83.
    O’Rourke T, Rodriguez G, Eckardt J, Kuhn J, Burris H, Hardy J, Weiss G, Von Hoff D: Phase I clinical trial of ormaplatin (NSC 363812) given on a dailyx5 every 28 day schedule. Proc Amer Assoc Cancer Res 1992 (33): Abs 3215Google Scholar
  84. 84.
    Trump DL, Petras W, Chaney S, Smith DC, Fangmeier J, Brown TD, Goldberg H: Phase I clinical trial and study of the pharmacokinetics and metabolism of ormaplatin (tetraplatin, NSC 363812). Proc Amer Assoc Cancer Res 1992 (33): Abs 3217Google Scholar
  85. 85.
    Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990 (25): 299–303PubMedGoogle Scholar
  86. 86.
    Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathé G: Phase I trial of 5 day continuous venous infusion of oxaliplatin at circadian rhythm — modulated rate compared with constant rate. JNCI 1990 (82): 1046–1050PubMedGoogle Scholar
  87. 87.
    Vermorken JB, ten Bokkel Huinink WW, McVie JG, van der Vijgh WJF, Pinedo HM: Clinical experience with 1, 1-diaminomethylcyclohexane (sulphato) platinum(II) (TN06). In: Hacker MP, Douple EB, Krakoff IJ (eds) Platinum Coordination Complexes in Cancer Chemotherapy. Martinus Nijhoff, Boston 1984 pp 330–343Google Scholar
  88. 88.
    Wagstaff AJ, Ward A, Benfield P, HeeJ RC: Carboplatin: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 1989 (37–2): 163–186Google Scholar
  89. 89.
    Yarbo JW (ed): Carboplatin (JM8) update: Current perspectives and future directions. Sem Oncol 1992(19 Suppl 2):1–164Google Scholar
  90. 90.
    Mangioni C, Bolis G, Pecorelli S, Bragman K, Epis A, Favalli G, Gambino A, Landoni F, Presti M, Torri W, Vassena L, Zanaboni F, and Marsoni S: Randomised trial in ovarian cancer comparing cisplatin and carboplatin. JNCI 1989 (81): 1464–1468PubMedGoogle Scholar
  91. 91.
    Advanced Ovarian Cancer Trialists Group: Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J 1991 (303) 884–893Google Scholar
  92. 92.
    Gore M, Fryatt I, Wiltshaw E, Dawson T, Robinson B and Clavert A: Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer 1989 (60) 767–769PubMedGoogle Scholar
  93. 93.
    Eisenhauer E, Swerton K, Sturgeon J, Fine S, O’Reilly S, Canetta R: Carboplatin therapy for recurrent ovarian carcinoma: National Cancer Institute of Canada experience and a review of the literature. In: Bunn P, Canetta R, Ozols R and Rozencweig M (eds) Carboplatin; Current Perspectives and Future Directions. WB Saunders Company, Philadelphia 1990 pp 133–140Google Scholar
  94. 94.
    Trask C, Silverstone A, Ash CM, Earl H, Irwin C, Bakker A, Tobias JS, Souhami RL: A randomized trial of carboplatin versus iproplatin in untreated ovarian cancer. J Clin Oncol 1991 (9): 1131–1137PubMedGoogle Scholar
  95. 95.
    Bitha P, Carvajal SG, Citarella RV, Delos Santos EF, Durr FE, Hlavka JJ, Lang SA, Lindsay HL, Thomas JP, Wallace RE, Lin Y: Water soluble third generation antitumour platinum complexes, [2,2-bis (aminomethyl)-1, 3-propanediol-N, N′] [1,1-cyclobutanedicarboxylato(2-)-O,O′] platinum(II) and [1,1-cyclobutanedicarboxylato(2-)-O,O′] [tetrahydro-4H-pyran-4, 4-dimethanamine-N,N′]. J Med Chem 1989 (32(8)): 2015–2020PubMedGoogle Scholar
  96. 96.
    Meijer C, Mulder NH, Timmer-Bosscha H, Meersma GJ, De Vries EG: Role of GSH in the efficacy of 7 platinum(Pt) compounds in 2 cisplatin(CDDP)-resistant human cell lines. Proc Amer Assoc Cancer Res 1991 (32): Abs 2427Google Scholar
  97. 97.
    Dodion PF, de Valeriola D, Crepeigne N, Kantrowitz JD, Piccart M, Wery F, Kergier J, Egorin MJ, Forrest A, Bachur NR, Alaerts P, Carver A, Rastogi R, Hammershaimb L, Saletan S: Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex. Annals Oncol 1991 (2): 589–596Google Scholar
  98. 98.
    Jones AL, Mckeage M, Davies C, Holburn J, Ashley SE, Rastogi R, Townsend H, Smith IE: Phase II study of zeniplatin in advanced non small cell lung cancer. Cancer Chemother Pharmacol 1992 (in press)Google Scholar
  99. 99.
    Aamdal S, Piccart M, Wanders J, Rastogi RB, Schwartsman G, Franklin HR, Kaye SB: Phase (II) study of zeniplatin/CL 286,558) [2,2-bis(aminomethyl)-1,3 propanediol-N,N′] [1,1-cyclobutanedicarboxylato(2-)O,O′] platinum(II) in patients with advanced melanoma. Poster presented at the Sixth International Symposium on platinum and other metal coordination compounds (San Diego, Ca) Jan (23–26) 1991, but not published in the conference proceedings Google Scholar
  100. 100.
    Olver I, Green M, Peters W, Zimet A, Toner G, Bishop J, Ketelbey W, Astogi R, Birkhofer M: A pilot phase (II) study of zeniplatin in metastatic melanoma. Annals Oncol 1992 (3 Suppl 1): Abs 345Google Scholar
  101. 101.
    Piccart M, Kerger J, Tueni E, van der Schueren E, Kennes C, Bartholomeus S, Vantongelen K, Rastogi R, Birkhofer M: Phase II trial of zeniplatin (CL 286, 558; ZNP) as second line treatment in metastatic breast cancer (MBC). Proc Amer Assoc Cancer Res 1991 (32): Abs 1222Google Scholar
  102. 102.
    Willemse PH, Giettera JA, Sleijfer DT, Mulder NH, de Vries EG, de Halleux F, Rastogi RB, Birkhofer M: Activity of a third generation platinum compound zeniplatin (CL 286, 558) in patients with recurrent ovarian cancer. Proc Amer Soc Clin Oncol 1991 (10): Abs 626Google Scholar
  103. 103.
    Ceulemans F, Duprez P, Vindevogel A, Tueni E, Piccart M, Kerger J, Rastogi R, de Halleux F: Enloplatin (CL287, 110): Phase I study in patients with advanced solid tumours. Poster presented at the Sixth International Symposium on platinum and other metal coordination compounds (San Diego, Ca) Jan (23–26) 1991, but not published in the conference proceedings Google Scholar
  104. 104.
    Majima H: Clinical studies with cisplatin analogues, 254-S, DWA 2114R and NK121. In: Howell SB (ed) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Plenum Press, New York 1991 pp 345–355Google Scholar
  105. 105.
    Fukuoka M, Niitani H, Hasegawa K, Majima H, Hino M, Furue H, Tsukagoshi S, Fujita H, Ohta K, Furuse K, Kimura I, Katoh T: Phase I study of a new platinum compound, NK121. Proc Amer Soc Clin Oncol 1989 (8): Abs 240Google Scholar
  106. 106.
    Hughes GR, O’Dwyer PJ, Walczak J, La Creta FP, Cohen I, Kowal C, Boyd RA, Whitfield LR: Phase I/pharmacokinetic study of the new platinum compound CI-973 on a 5-day schedule. Proc Amer Assoc Cancer Res 1991 (32): Abs 1190Google Scholar
  107. 107.
    Ariyoshi Y, Ota K: Preclinical and clinical evaluation of toxicities and antitumour activities of cisplatin analogues. Jpn J Cancer Chemother 1989 (16): 1379–1385Google Scholar
  108. 108.
    Tamura K, Makino S, Araki Y: A phase I study of a new cisplatin derivative for haematological malignancies. Cancer 1990 (66): 2059–2063PubMedGoogle Scholar
  109. 109.
    Ariyoshi Y, Ota K, Wakui A, Majima H, Niitani H, Ogawa M, Imuyama Y, Yoshida O, Taguchi T, Kimura I, Kato T: Phase I study of [glycolato-O,O′] diammine platinum(II) (254–5). Proc Amer Soc Clin Oncol 1988 (7): Abs 222.Google Scholar
  110. 110.
    Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Kojima A, Saijo N: Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum(II) (254–5; NSC 375101d) administered by 5-day continuous intravenous infusion. Cancer Res 1991 (51): 1472–1477PubMedGoogle Scholar
  111. 111.
    Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe-Y, Kojima A, Oshita F, Hara K, Saijo N: Phase II study of (glycolate-O,O′) diammine-platinum(II), a novel platinum complex in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol 1990 (26): 393–396PubMedGoogle Scholar
  112. 112.
    Kelley SL, Rozencweig M: Resistance to platinum compounds: mechanisms and beyond. Eur J Cancer Clin Oncol 1989 (25): 1135–1140PubMedGoogle Scholar
  113. 113.
    Scanlon KJ, Kashani-Sabet M, Tone T, Funato T. Cisplatin resistance in human cancers. Pharmac Ther 1991 (52): 385–406Google Scholar
  114. 114.
    Kuwai K, Kumatani N, Georges E, Ling V: Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminodichloroplatinum(II). J Biol Chem 1990 (265) 13137–13142Google Scholar
  115. 115.
    Pil PM, Lippard SJ: Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 1992 (256): 234–237PubMedGoogle Scholar
  116. 116.
    Enns RE and Howell SB: Isolation of a gene associated with resistance to cisplatin. In: Howell SB (ed) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Plenum Press, New York 1991 pp 213–219Google Scholar
  117. 117.
    Basu A, Kozikowski AP, Sato K, Lazo JS: Cellular sensitisation to cis-diamminodichloro platinum (II) by novel analogues of the protein kinase C activator lyngbyatoxin A. Cancer Res 1991 (51): 2511–2514PubMedGoogle Scholar
  118. 118.
    Basu A, Lazo JS: Sensitization of human cervical carcinoma cells to cis-diamminedichloroplat-inum(II) by bryostatin 1. Cancer Res 1991 (52): 3119–3124Google Scholar
  119. 119.
    Eastman A: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990 (2): 275–280PubMedGoogle Scholar
  120. 120.
    Isonishi S, Horn DK, Thiebaut FB, Mann SC, Andrews PA, Basu A, Lazo JS, Eastman A, Howell SB: Expression of the C-Ha-ras oncogene in mouse NIH3T3 cells induces resistance to cisplatin. Cancer Res 1991 (51): 5903–5909PubMedGoogle Scholar
  121. 121.
    Niimi S, Nakagawa K, Yokata J, Tsunokawa Y, Nishio K, Terashima Y, Shibuya M, Terada M, Saijo N: Resistance to anticancer drugs in NIH 3T3 cells transfected with c-myc and/or c-Ha-ras oncogenes. Br J Cancer 1991 (63): 237–241PubMedGoogle Scholar
  122. 122.
    Scanlon KJ, Jiao L, Funato T, Wang W, Tone T, Rossi JJ, Kashani-Sabet M: Ribozyme-mediated cleavage of c-fos m RNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci (USA) 1991 (88): 10591–10595Google Scholar
  123. 123.
    Rubin E, Kharbanda S, Gunji H, Weichselbaum R, Kufe D: Cis-diamminedichloro platinum(II) induces c-jun expression in human myeloid leukaemia cells: potential involvement of a protein kinase C-dependent signalling pathway. Cancer Res 1992 (52): 878–882PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • Kenneth R. Harrap
    • 1
  1. 1.Drug Development SectionThe Institute of Cancer Research: Royal Cancer HospitalSuttonUK

Personalised recommendations